地尔硫联合卡托普利治疗小儿肺动脉高压的疗效观察

目的:观察地尔硫卓联合卡托普利治疗小儿肺动脉高压(PAH)的疗效及安全性。方法:将60例符合条件的患儿随机分成A、B、C组,每组各20例,分别给予地尔硫卓、卡托普利、地尔硫卓联合卡托普利,每组服药时间均为6个月。观察3组用药前、后体循环收缩压(SBP)、舒张压(DBP)和心率(HR),肺循环平均肺动脉压(mPAP)以及肺血管阻力(PVR)等指标变化,记录用药期间的不良反应。结果:用药后,三组SBP、DBP、HR均下降,C组SBP、HR下降明显(P<0.05);A、B组mPAP、PVR较用药前下降(P<0.05),且C组下降更明显(P<0.01),与A、B组相比,C组下降有统计学意义(P<0.05);各组均未见严重不良反应。结论:地尔硫卓联合卡托普利治疗小儿PAH更有效,且安全。

Efficacy Observation of Diltiazem Combined with Captopril in the Treatment of Pulmonary Artery Hypertension

Objective:To observe effectiveness and safety of diltiazem combined with captopril in the treatment of children’s pulmonary artery hypertension(PAH).Methods:62 eligible children were randomly divided into group A,B,C.They were given diltiazem,captopril,combined therapy of diltiazem and captopril respectively for 6months.The changes of systemic bloood pressure(SBP).diastolic blood pressure(DBP),heart rate(HR),mean pulmonary artery pressure(mPAP) and pulmonary vascular resistance(PVR) in 3 groups were observed before and after administration,and adverse drug reactions were recorded.Results:After administration,,SBP,DBP,HR were decreased in 3 group,and SBP and HR in group C were decreased significatly.mPAP and PVR in group A and C were dropped(P<0.05),and mPAP and PVR in group C were dropped obviously(P<0.01).Compared with group A and B,decreasing of mPAP and PVR in group C had statistical significance(P<0.05).Severe adverse drug reaction was not found in each group Conclusion:Combined therapy of diltiazem and captopril is more efective and safe in the treatment of children’s PAH.